GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » Price-to-Operating-Cash-Flow

IRD (Opus Genetics) Price-to-Operating-Cash-Flow : (As of Jun. 26, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Price-to-Operating-Cash-Flow?

As of today (2025-06-26), Opus Genetics's share price is $0.9702. Opus Genetics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.99. Hence, Opus Genetics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Opus Genetics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 6 years, Opus Genetics's highest Price-to-Operating-Cash-Flow Ratio was 9.69. The lowest was 2.73. And the median was 4.87.

IRD's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.095
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Opus Genetics's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.27. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.99.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 9.80% per year.

During the past 6 years, Opus Genetics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.10% per year. The lowest was 9.80% per year. And the median was 38.45% per year.


Opus Genetics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Opus Genetics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Price-to-Operating-Cash-Flow Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - 5.08 - -

Opus Genetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Opus Genetics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Opus Genetics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Price-to-Operating-Cash-Flow falls into.


;
;

Opus Genetics Price-to-Operating-Cash-Flow Calculation

Opus Genetics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.9702/-0.988
=

Opus Genetics's Share Price of today is $0.9702.
Opus Genetics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.99.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Opus Genetics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Opus Genetics Business Description

Industry
Traded in Other Exchanges
Address
8 Davis Drive, Suite 220, Durham, NC, USA, 27709
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Executives
George Magrath officer: Chief Executive Officer 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel officer: SVP, Operations & Bus. Dev. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch director, officer: President and CEO 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J director 5130 ROUTE 212, WILLOW NY 12495
Jay Pepose director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton director 3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba officer: VP of Finance 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer director
Sean Ainsworth director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann officer: VP of Corp. Dev. & Ops & Sec. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price director 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky officer: President and CFO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732